Novartis Receives FDA Approval for Skin Condition Treatment
MT Newswires Live
Oct 01
Novartis (NVS) said late Tuesday the US Food and Drug Administration has approved Rhapsido for adult patients with chronic spontaneous urticaria who remain symptomatic despite H1 antihistamine treatment.
Chronic spontaneous urticaria is a skin condition characterized by the appearance of itchy hives and swelling.
The company said the approval was based on the results of two phase 3 trials, where Rhapsido demonstrated "superiority" in change from baseline, compared with placebo, in itch, hives, and weekly urticaria activity at week 12.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.